MAMiranda Addie

Miranda Addie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miranda Addie has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Ericka Iny

    McGill University Medical School, Montreal, QC, Canada

    3 shared publications
  • Stephanie M. Wong

    Department of Surgical and Interventional Sciences, McGill University, Montreal, QC, Canada; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Canada

    3 shared publications
  • Ipshita Prakash

    Department of Surgical and Interventional Sciences, McGill University, Montreal, QC, Canada; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Canada

    2 shared publications
  • Sarkis Meterissian

    Division of Surgical and Interventional Science Department of Surgery McGill University Montreal Canada

    2 shared publications
  • Adda-Lee Graham-Paquin

    1 shared publication
  • Adéline Massé

    1 shared publication

Latest Publications

  • Open Access

    Neutrophil elastase-mediated myoepithelial loss is a therapeutic vulnerability in ductal carcinoma in situ progression

    by Tarek Taifour, Yu Gu, Adéline Massé, Xiwei Meng, Clarisse Dane Echavez, Dongmei Zuo, Virginie Sanguin-Gendreau, Anne Blouin, Adda-Lee Graham-Paquin, Miranda Addie, et al.

  • Patients with positive axillary nodes undergoing upfront surgery: Can axillary dissection be safely omitted?

    by Miranda Addie, Alexander-Darius Miron, Ericka Iny, Stephanie M. Wong, Vanessa M.S. Ross, Ipshita Prakash, Sarkis Meterissian


  • Open Access

    Axillary Management for Patients Undergoing Total Mastectomy and a Positive Sentinel Lymph Node: Is Axillary Dissection Necessary?

    by Miranda Addie, Alexander‐Darius Miron, Ericka Iny, Basmah Alhassan, Amina Ferroum, Stephanie M. Wong, Ipshita Prakash, Tarek Hijal, Sarkis Meterissian

    Purpose: We sought to evaluate whether patients with breast cancer who undergo a total mastectomy (TM) can safely forgo a completion axillary lymph node dissection (cALND) in the presence of one to three positive sentinel lymph nodes (SLN+).Methods: A multicenter retrospective cohort study (2012–2022) was conducted in patients with cT1‐3cN0 who underwent TM with 1–3 SLN+ compared by cALND versus. no further surgery. We compared overall survival (OS) and locoregional recurrence rates (LRR) and investigated whether the omission of cALND altered adjuvant treatment.Results: In total, the study included 139 patients with SLN+TM, with a mean tumor size of 19.44 mm (SD:10.64); 76% (n = 105) of these patients underwent SLNB‐alone. Patients treated by cALND had a younger mean age than those treated by SLNB‐alone (49.5 vs. 56 years and p = 0.016). Patients undergoing cALND were more likely to have macrometastatic disease (97% vs. 65% and p < 0.001) and extranodal extension (47% vs. 29% and p = 0.046). cALND was associated with higher rates of adjuvant chemotherapy (88% vs. 62% and p = 0.004). Postmastectomy radiotherapy (PMRT) was similar between groups (79% vs. 82% and p = 0.68). At a mean follow‐up of 5.2 years, there was one chest‐wall LRR in the SLNB group, with no axillary recurrences. LRR did not significantly differ with or without cALND (2.9% vs. 1.0% and p = 0.4). Five‐year overall survival rates were similar between groups (100% vs. 94% and p = 0.2).Conclusion: We found high OS and low LRR among patients undergoing upfront TM with 1–3 SLN+ without cALND. Completion ALND did not decrease receipt of PMRT but was associated with higher rates of adjuvant chemotherapy. Our findings support the omission of cALND after TM for patients with 1–3 SLN+.


  • Open Access

    Oncologic safety of breast conserving surgery after neoadjuvant chemotherapy in patients with multiple ipsilateral breast cancer: A retrospective multi-institutional cohort study

    by Élise Di Lena, Stephanie M. Wong, Ericka Iny, Sarah Mashal, Mark Basik, Jean-François Boileau, Karyne Martel, Miranda Addie Bassel, Sarkis Meterissian, Ipshita Prakash


  • Open Access

    P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study

    by B Bressler, A Yarur, U Kopylov, M Bassel, N Brett, C Colby, C Lopez, S Saha, C Kifnidi, C Agboton, et al.

    There is little long-term research (≥12 months) in ulcerative colitis (UC) and Crohn’s disease (CD) patients investigating the impact on clinical effectiveness of combined (combo) therapy of vedolizumab (VDZ) plus immunomodulators/immunosuppressants (IMMs) compared with VDZ monotherapy. Research suggests the use of concomitant aminosalicylates [5-ASAs] in UC may not bolster effectiveness. Finally, it is unclear if the safety profile differs between VDZ monotherapy and combo therapy. This study described clinical effectiveness and safety outcomes in patients with UC or CD treated with first-line biologic VDZ as monotherapy or combo therapy with IMMs or 5-ASAs (UC only). This was a real-world, multi-country (Canada, Greece and the USA), retrospective chart review study of biologic-naïve UC and CD patients (≥18 years old) treated with VDZ (initiated Tx May 2014–March 2018). Data were collected from Tx initiation to the earliest of death and chart abstraction date. Cumulative rates of clinical effectiveness outcomes over 24 months (Tx persistence, clinical response and clinical remission) were estimated using the Kaplan-Meier method with unadjusted comparisons conducted using the log-rank test. Clinical response and remission were assessed from standard disease measures reported in medical records. Analyses of unadjusted incidence rates (per 100 person-years [PYs]) of disease exacerbations, disease-related surgeries, serious adverse events (SAEs) and serious infections (SIs) were performed. For these analyses in monotherapy vs. VDZ+IMMs, UC and CD patients were combined due to restrictions of sample size and a number of events. This analysis included 318 patients treated with VDZ (monotherapy: UC = 53, CD = 108; VDZ+IMMs: UC = 22, CD = 24; VDZ+5-ASAs: UC = 111). There were no observed differences in age, sex or disease duration between patients on monotherapy vs. VDZ+IMMs or vs. VDZ+5-ASAs. Data trends in effectiveness outcomes were similar in monotherapy vs. VDZ+IMMs over 24 months (Figure 1). Tx persistence (monotherapy: 71.6%; VDZ+5-ASAs: 82.7%; p = 0.40), clinical remission (monotherapy: 54.3%; VDZ+5-ASAs: 87.7%; p = 0.37) and clinical response (monotherapy: 81.7%; VDZ+5-ASAs: 92.2%; p = 0.54) were also similar between monotherapy and VDZ+5-ASAs over 24 months. Safety outcomes were similar between groups (Figure 2). Though sample sizes were small, the unadjusted trends in the results of this long-term real-world study suggest that biologic-naïve UC or CD patients treated with VDZ alone may have similar clinical effectiveness outcomes to patients receiving VDZ+IMMs. Trends in data also suggest that in patients with UC, VDZ+5-ASAs may not be more effective than VDZ alone.